Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Common Equity: 2022-2025

Historic Common Equity for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $728.1 million.

  • NewAmsterdam Pharma Co N.V's Common Equity rose 92.17% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $728.1 million, marking a year-over-year increase of 92.17%. This contributed to the annual value of $757.5 million for FY2024, which is 162.66% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Common Equity stood at $728.1 million, which was down 6.48% from $778.5 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Common Equity's 5-year high stood at $778.5 million during Q2 2025, with a 5-year trough of $288.4 million in Q4 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Common Equity averaged around $510.1 million, with its median value being $398.4 million (2023).
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Common Equity tumbled by 32.94% in 2023, and later surged by 162.66% in 2024.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Common Equity stood at $430.1 million in 2022, then tumbled by 32.94% to $288.4 million in 2023, then spiked by 162.66% to $757.5 million in 2024, then soared by 92.17% to $728.1 million in 2025.
  • Its Common Equity stands at $728.1 million for Q3 2025, versus $778.5 million for Q2 2025 and $777.4 million for Q1 2025.